SCHEMBL6443352

SCHEMBL6443352

O=C(c1ccccc1)N1CCN(C2CCN(C(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)CC2c2ccccc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 2/20 0.50
RHOC P08134 3/20 0.47
RHOA P61586 3/20 0.47
CYP3A4 P08684 2/20 0.47
TSHR P16473 1/20 0.47
USP2 O75604 3/20 0.46
HSD17B10 Q99714 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
ATM Q13315 1/20 0.46
RBP4 P02753 1/20 0.45
TACR1 P25103 2/20 0.45
MGLL Q99685 1/20 0.44
ACACB O00763 1/20 0.44
ACACA Q13085 1/20 0.44
CCR5 P51681 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6443346 1.00 SLC18A3 (0.50) SLC18A3RHOCRHOACYP3A4TSHR
SCHEMBL6441492 0.98 RHOA (0.49) SLC18A3RHOCRHOACYP3A4TSHR
SCHEMBL6441487 0.98 RHOA (0.49) SLC18A3RHOCRHOACYP3A4TSHR
SCHEMBL6440256 0.94 RHOA (0.45) SLC18A3RHOCRHOACYP3A4TSHR
SCHEMBL6440261 0.94 RHOA (0.45) SLC18A3RHOCRHOACYP3A4TSHR
SCHEMBL6442812 0.92 TACR1 (0.52) SLC18A3RHOCRHOACYP3A4TSHR
SCHEMBL6442815 0.92 TACR1 (0.52) SLC18A3RHOCRHOACYP3A4TSHR
SCHEMBL6442173 0.92 KDM1A (0.46) SLC18A3RHOCRHOACYP3A4TSHR
SCHEMBL6442171 0.92 KDM1A (0.46) SLC18A3RHOCRHOACYP3A4TSHR
SCHEMBL5918246 0.92 CYP3A4 (0.47) SLC18A3RHOCRHOACYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1360184-B1 PIPERIDINE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2005-03-30 EP disclosed
US-6642226-B2 Such as cis-(3,5-bis-trifluoromethyl-phenyl)-(4-(4-methyl-piperazin-1-yl),-3-phenyl -piperidin-1-yl)-methanone; for treatment of diseases related to neurokinin receptors HOFFMAN-LA ROCHE INC. 2003-11-04 US disclosed
US-20020151547-A1 Substituted phenyl-piperidine methanone compounds F.HOFFMANN-LA ROCHE AG (CH) 2002-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151547-A1 Substituted phenyl-piperidine methanone compounds TACR1, OPRK1, TACR2 SLC18A3 2396/4885RHOC 3239/4885RHOA 4345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.